Cyclical combination chemotherapy and thyroid function in patients with advanced Hodgkin's disease.
Clinical and biochemical assessment of thyroid function was undertaken in patients with Hodgkin's disease at designated points following diagnosis. At diagnosis, two of 20 patients had either abnormally low routine thyroid indices, or elevated thyroid stimulating hormone (TSH) levels that were not due to iodine-based investigations. Following lymphography, 76.5% of patients had TSH levels that remained elevated for a median period of 3 months. No detectable thyroid dysfunction was induced during chemotherapy. Fifty-four patients were studied at a median time of 35 months after chemotherapy. One euthyroid patient had a nodular goitre, and one had abnormal thyroid indices. Tsh levels were elevated in 44% of patients, although the median TSH level for the group was normal. Half the patients had abnormal TRH stimulation tests. Sixty patients were studied after irradiation and chemotherapy. Four patients had clinical thyroid dysfunction, and 10% of routine thyroid indices were abnormal. TSH levels were abnormal in 80%, with a markedly elevated median level. All thyroid releasing hormone stimulation tests were abnormal.
D000970:Antineoplastic Agents / Q000009:adverse effects*; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000532:radiotherapy; D006801:Humans; D012189:Retrospective Studies; D013960:Thyroid Function Tests; D013961:Thyroid Gland / Q000187:drug effects / Q000503:physiopathology*; D013972:Thyrotropin / Q000032:analysis; D013973:Thyrotropin-Releasing Hormone / Q000032:analysis
D000970:Antineoplastic Agents; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin